Abstract 3697
Background
Pancreatic neuroendocrine tumor (pNET) is rare and heterogeneous. New biomarkers are needed for better predicting the prognosis and providing individualized treatment. Versican (VCAN) plays an important role in tumorigenesis. Our previous study showed VCAN was specifically expressed in pNET tumor tissue. Therefore, we planned to investigate the role of VCAN in pNET prognosis.
Methods
Clinical and pathological data of pNET patients who underwent surgery between 2005 and 2010 were followed up and evaluated. VCAN expression was assessed by immunohistochemical (IHC) methods, and the relationship between VCAN and prognostic features of pNET was analyzed.
Results
Among 161 pNET patients, 118 (73.3%) pNET were VCAN expression positive and 43 (26.7%) VCAN expression negative. Positive expression of VCAN in pNET was significantly associated with longer disease-free survival (DFS) compared with VCAN-negative pNET (p = 0.017, HR 0.399, 95%CI 0.215-0.741). Subgroup analysis showed that VCAN-positive expression was associated with longer DFS in the G1 subgroup (p = 0.030, HR = 0.122, 95%CI: 0.013-1.180), tumor size>2cm subgroup (p = 0.030, HR = 0.427, 95%CI: 0.193-0.944) and NF-pNET subgroup (p = 0.001, HR = 0.251, 95%CI: 0.103-0.617). Multiple analysis showed that VCAN-negative expression, G2 and tumor size>2cm were independent factors for poor prognosis in pNET (p = 0.01, p < 0.001, p = 0.009, respectively).
Conclusions
Our data indicate that VCAN-positive expression may serve as an independent factor for predicting DFS prognosis in pNET. VCAN-positive expression in pNET tissues was correlated with longer DFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5773 - A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus.
Presenter: Rebecca Muirhead
Session: Poster Display session 2
Resources:
Abstract
4581 - Timing to achieve complete response (CR) after definitive chemoradiotherapy (ChRT) in patients with squamous cell carcinoma of the anal (SCCAC) with and without HIV infection: a multicenter retrospective study
Presenter: Marcos Camandaroba
Session: Poster Display session 2
Resources:
Abstract
1712 - Planned organ preservation for T2 T3 M0 rectal adenocarcinoma. A possible option using chemoradiotherapy (CRT) and Contact X-ray Brachytherapy (CXB). A French multicenter study.
Presenter: Jean-Pierre Gérard
Session: Poster Display session 2
Resources:
Abstract
4639 - A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer
Presenter: Lucjan Wyrwicz
Session: Poster Display session 2
Resources:
Abstract
2310 - Upfront radical surgery with total mesorectal excision (TME) versus preoperative chemoradiotherapy followed by TME in clinical stage II/III patients with rectal cancer: a propensity score analysis
Presenter: Ahrong Ham
Session: Poster Display session 2
Resources:
Abstract
2747 - Neoadjuvant chemoradiotherapy with/without lateral lymph node dissection for low rectal cancer: Which patients can benefit?
Presenter: Daisuke Nishizaki
Session: Poster Display session 2
Resources:
Abstract
2877 - The impact of completeness of chemotherapy on the efficacy of irinotecan in the preoperative chemoradiotherapy of locally advanced rectal cancer.
Presenter: Jingwen Wang
Session: Poster Display session 2
Resources:
Abstract
3050 - Feasibility of robot-assisted surgery in elderly patients with rectal cancer
Presenter: Wei-Chih Su
Session: Poster Display session 2
Resources:
Abstract
4109 - Feasibility of chemoradiotherapy in rectal cancer patients with peritumoral abscesses and fistulas: a case-control non-inferiority trial
Presenter: Valerii Ivanov
Session: Poster Display session 2
Resources:
Abstract
4813 - Differential of the nutritional index before and after neoadjuvant chemoradiotherapy as a prognostic factor of recurrence in patients with locally advanced adenocarcinoma of the rectum
Presenter: Leslie Navia-Ortuño
Session: Poster Display session 2
Resources:
Abstract